NCT05875259View on ClinicalTrials.gov

A Clinical Trial Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1019-1 and BR1019-2 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 13, 2023

Primary Completion Date

June 29, 2023

Study Completion Date

June 29, 2023

Conditions
HypertensionDiabetes Mellitus, Type 2
Interventions
DRUG

BR1019-1

Treatment group A : One tablet of BR1019-1 administered alone once daily for 7 days.

DRUG

BR1019-2

Treatment group B : One tablet of BR1019-2 administered alone once daily for 7 days.

DRUG

BR1019-1 + BR1019-2

Treatment group C : One tablet each of BR1019-1 and BR1019-2 administered in combination once daily for 7 days.

Trial Locations (1)

Unknown

Inha University Hospital, Incheon

Sponsors
All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY

NCT05875259 - A Clinical Trial Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1019-1 and BR1019-2 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter